These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 27876274)

  • 1. Are there any ways around the exposure-limiting nephrotoxicity of the polymyxins?
    Pogue JM; Ortwine JK; Kaye KS
    Int J Antimicrob Agents; 2016 Dec; 48(6):622-626. PubMed ID: 27876274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical considerations for optimal use of the polymyxins: A focus on agent selection and dosing.
    Pogue JM; Ortwine JK; Kaye KS
    Clin Microbiol Infect; 2017 Apr; 23(4):229-233. PubMed ID: 28238870
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adverse reactions associated with systemic polymyxin therapy.
    Justo JA; Bosso JA
    Pharmacotherapy; 2015 Jan; 35(1):28-33. PubMed ID: 25266910
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imaging the distribution of polymyxins in the kidney.
    Yun B; Azad MA; Wang J; Nation RL; Thompson PE; Roberts KD; Velkov T; Li J
    J Antimicrob Chemother; 2015 Mar; 70(3):827-9. PubMed ID: 25377569
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro assessment and multicenter cohort study of comparative nephrotoxicity rates associated with colistimethate versus polymyxin B therapy.
    Phe K; Lee Y; McDaneld PM; Prasad N; Yin T; Figueroa DA; Musick WL; Cottreau JM; Hu M; Tam VH
    Antimicrob Agents Chemother; 2014 May; 58(5):2740-6. PubMed ID: 24566187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Polymyxins - review with emphasis on nephrotoxicity].
    Mendes CA; Burdmann EA
    Rev Assoc Med Bras (1992); 2009; 55(6):752-9. PubMed ID: 20191233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and pharmacodynamics of 'old' polymyxins: what is new?
    Bergen PJ; Landersdorfer CB; Zhang J; Zhao M; Lee HJ; Nation RL; Li J
    Diagn Microbiol Infect Dis; 2012 Nov; 74(3):213-23. PubMed ID: 22959816
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Low-Alkalinity Polymyxin Derivative, AL-6, Shows High Activity Against Multidrug-Resistant
    Chen DJ; Cui AL; Chen JR; Yang P; Jin J; Shao L; Li ZR
    Microb Drug Resist; 2021 Jul; 27(7):933-941. PubMed ID: 33544031
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The safety of polymyxin antibiotics.
    Kelesidis T; Falagas ME
    Expert Opin Drug Saf; 2015; 14(11):1687-701. PubMed ID: 26365594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polymyxin-induced nephrotoxicity and its predictors: a systematic review and meta-analysis of studies conducted using RIFLE criteria of acute kidney injury.
    Sisay M; Hagos B; Edessa D; Tadiwos Y; Mekuria AN
    Pharmacol Res; 2021 Jan; 163():105328. PubMed ID: 33276108
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nephrotoxicity of Polymyxins: Is There Any Difference between Colistimethate and Polymyxin B?
    Zavascki AP; Nation RL
    Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 27993859
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk factors for acute kidney injury in patients treated with polymyxin B or colistin methanesulfonate sodium.
    Tuon FF; Rigatto MH; Lopes CK; Kamei LK; Rocha JL; Zavascki AP
    Int J Antimicrob Agents; 2014 Apr; 43(4):349-52. PubMed ID: 24439066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections.
    Falagas ME; Kasiakou SK
    Clin Infect Dis; 2005 May; 40(9):1333-41. PubMed ID: 15825037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics/pharmacodynamics of colistin and polymyxin B: are we there yet?
    Tran TB; Velkov T; Nation RL; Forrest A; Tsuji BT; Bergen PJ; Li J
    Int J Antimicrob Agents; 2016 Dec; 48(6):592-597. PubMed ID: 27793510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rescuing the Last-Line Polymyxins: Achievements and Challenges.
    Nang SC; Azad MAK; Velkov T; Zhou QT; Li J
    Pharmacol Rev; 2021 Apr; 73(2):679-728. PubMed ID: 33627412
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polymyxins revisited.
    Landman D; Georgescu C; Martin DA; Quale J
    Clin Microbiol Rev; 2008 Jul; 21(3):449-65. PubMed ID: 18625681
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nephrotoxicity in Patients with or without Cystic Fibrosis Treated with Polymyxin B Compared to Colistin.
    Crass RL; Rutter WC; Burgess DR; Martin CA; Burgess DS
    Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28167560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute kidney injury with intravenous colistin sulfate compared with polymyxin B in critically ill patients: A real-world, retrospective cohort study.
    Yang QJ; Xiang BX; Song MH; Yang CY; Liang JH; Xie YL; Zuo XC
    Pharmacotherapy; 2024 Aug; 44(8):631-641. PubMed ID: 39046197
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of intravenous and aerosolized polymyxins for the treatment of infections in critically ill patients: a review of the recent literature.
    Falagas ME; Kasiakou SK; Tsiodras S; Michalopoulos A
    Clin Med Res; 2006 Jun; 4(2):138-46. PubMed ID: 16809407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Methionine Ameliorates Polymyxin-Induced Nephrotoxicity by Attenuating Cellular Oxidative Stress.
    Azad MAK; Sivanesan S; Wang J; Chen K; Nation RL; Thompson PE; Roberts KD; Velkov T; Li J
    Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29061752
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.